{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:26:33Z","timestamp":1786926393987,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jacl.2019.06.002","type":"journal-article","created":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T16:32:00Z","timestamp":1561653120000},"page":"586-593.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3\u00a0trials"],"prefix":"10.1016","volume":"13","author":[{"given":"Keith C.","family":"Ferdinand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Elassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2019.06.002_bib1","first-page":"143","article-title":"Racial and ethnic differences in cardiovascular disease risk factors: a systematic review","volume":"17","author":"Kurian","year":"2007","journal-title":"Ethn Dis"},{"key":"10.1016\/j.jacl.2019.06.002_bib2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1161\/01.CIR.0000158136.76824.04","article-title":"State of disparities in cardiovascular health in the United States","volume":"111","author":"Mensah","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.002_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/CIR.0000000000000366","article-title":"Executive summary: heart disease and stroke statistics\u20132016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.002_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2019.06.002_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.09.002","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2019.06.002_bib6","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.2012.14517","article-title":"Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic\/Latino individuals of diverse backgrounds in the United States","volume":"308","author":"Daviglus","year":"2012","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jacl.2019.06.002_bib7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2019.06.002_bib8","series-title":"Cardiovascular outcomes with alirocumab after acute coronary syndrome: results of the ODYSSEY outcomes trial","author":"Schwartz","year":"2018"},{"key":"10.1016\/j.jacl.2019.06.002_bib9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2019.06.002_bib10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2019.06.002_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.amjcard.2017.06.023","article-title":"Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II)","volume":"120","author":"El Shahawy","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2019.06.002_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2019.06.002_bib13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2014.04.035","article-title":"Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans","volume":"235","author":"Enkhmaa","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2019.06.002_bib14","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/pgmj.2004.028274","article-title":"Diabetes in African Americans","volume":"81","author":"Marshall","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jacl.2019.06.002_bib15","doi-asserted-by":"crossref","first-page":"e004264","DOI":"10.1161\/JAHA.116.004264","article-title":"Race-sex differences in statin use and low-density lipoprotein cholesterol control among people with diabetes mellitus in the reasons for geographic and racial differences in stroke study","volume":"6","author":"Gamboa","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.06.002_bib16","doi-asserted-by":"crossref","first-page":"e005449","DOI":"10.1161\/JAHA.116.005449","article-title":"Vulnerabilities to health disparities and statin use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study","volume":"6","author":"Schroff","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.06.002_bib18","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamacardio.2018.1511","article-title":"Association of patient perceptions of cardiovascular risk and beliefs on statin drugs with racial differences in statin use: insights from the patient and provider assessment of lipid management registry","volume":"3","author":"Nanna","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacl.2019.06.002_bib19","first-page":"15","article-title":"A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States","volume":"6","author":"Lipworth","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jacl.2019.06.002_bib20","doi-asserted-by":"crossref","first-page":"e002905","DOI":"10.1161\/JAHA.115.002905","article-title":"Statin and aspirin use among hispanic and latino adults at high cardiovascular risk: findings from the hispanic community health study\/study of latinos","volume":"5","author":"Qato","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2019.06.002_bib21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2010.08.043","article-title":"Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease","volume":"153","author":"Bays","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacl.2019.06.002_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10557-018-6792-z","article-title":"Correction to: assessment of the 1% of patients with consistent < 15% reduction in low-density lipoprotein cholesterol: pooled analysis of 10 phase 3 ODYSSEY alirocumab trials","volume":"32","author":"Bays","year":"2018","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287419302144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T11:23:41Z","timestamp":1569583421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287419302144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1933287419302144"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2019.06.002","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3\u00a0trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2019.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}